Skip to main content

Is resveratrol the new aspirin for heart attacks?

The newswires are abuzz this month about a recent report suggesting that resveratrol, the polyphenol molecule from red wine, helps restore blood flow and limit muscle damage after heart attack. The typical headline reads something like “Red wine component pill successful during heart attacks” or something similar, with the clear implication that some sort of clinical trial has been done. In fact, it was a study in mice, and while the results were impressive it is only one small step toward the giant leap of clinical practice. What happens in mice doesn’t always happen in humans, so we are no where near the point where your cardiologist is going to give you a resveratrol pill when you show up in the E.R. with chest pain.


Nevertheless, the results are encouraging. What happens in a heart attack is that the plaques that build up in the coronary arteries that feed the heart muscle cause a clot to form, completely obstructing the vessel and depriving the heart of oxygen. It’s similar to what happens to the brain in a stroke. This oxygen starvation is called “ischemia” and when the clot is dissolved and blood flow re-established, it is called “reperfusion.” Paradoxically, this rush of blood flow releases toxins that have built up in the cells, resulting in what is called “ischemia-reperfusion injury.” Transplant surgeons deal with a related issue. The ability of resveratrol to counteract the detrimental effects of ischemia-reperfusion has been well documented in numerous studies, and the recent one in mice confirms those findings. But a mouse heart is tiny, and the question of whether the same effect applies in the large muscle mass of the human heart remains speculative.

A likely scenario is that one of the synthetic derivatives of resveratrol, many of which are much more potent, will emerge as a viable therapy for heart attack and stroke. But clinical studies on resveratrol are few in number, as I have pointed out here recently.

Comments

Popular posts from this blog

Versatile resveratrol: the ultimate skin care ingredient?

  Part 1 Recently I was honored to join Professors David Sinclair of Harvard and Joseph Vercauteren of the University of Montpelleir at an anti-aging symposium at the invitation of Mathilde Thomas of Caudalie in Paris. Caudalie has been using wine extracts (and specifically resveratrol) in their products for more than 15 years, after Vercauteren identified it in wine grape vines. Sinclair has become well known for his work identifying the role of sirtuin (SIRT) genes in anti-aging, and resveratrol as a natural sirtuin activator. While much remains to be proven, it is fair to say that science is finally beginning to have an impact on skin care. With an increasing understanding of what causes aging in skin cells and how botanical antioxidants such as resveratrol work at a molecular level, there is no excuse to use anti-aging skin care products that don’t multitask. Before delving into the potential benefits of resveratrol in skin care, it may help to review ho...

Revisiting resveratrol: new findings rekindle anti-aging debate

Just when we thought the bloom was off the rosé for resveratrol, the anti-oxidant polyphenol from red wine with multiple anti-aging properties, along comes new research giving life to the debate. But first a bit of background: As I detailed in my book Age Gets Better with Wine , it is well-documented that wine drinkers live longer and have lower rates of many diseases of aging. Much or the credit for this has been given to resveratrol, though there isn’t nearly enough of it in wine to explain the effects. Nevertheless, I dubbed it the “miracle molecule” and when it was reported to activate a unique life-extension phenomenon via a genetic trigger called SIRT, an industry was born, led by Sirtris Pharmaceuticals, quickly acquired by pharma giant Glaxo. The hope was that resveratrol science could lead to compounds enabling people to live up to 150 years and with a good quality of life. But alas, researchers from other labs could not duplicate the results, and clinical studies disa...